[COVID-19 in the intensive care unit].
Intensivmedizinische Therapie von COVID-19.
Journal
Pneumologie (Stuttgart, Germany)
ISSN: 1438-8790
Titre abrégé: Pneumologie
Pays: Germany
ID NLM: 8906641
Informations de publication
Date de publication:
May 2024
May 2024
Historique:
medline:
18
5
2024
pubmed:
18
5
2024
entrez:
17
5
2024
Statut:
ppublish
Résumé
The acute respiratory failure as well as ARDS (acute respiratory distress syndrome) have challenged clinicians since the initial description over 50 years ago. Various causes can lead to ARDS and therapeutic approaches for ARDS/ARF are limited to the support or replacement of organ functions and the prevention of therapy-induced consequences. In recent years, triggered by the SARS-CoV-2 pathogen, numerous cases of acute lung failure (C-ARDS) have emerged. The pathophysiological processes of classical ARDS and C-ARDS are essentially similar. In their final stages of inflammation, both lead to a disruption of the blood-air barrier. Treatment strategies for C-ARDS, like classical ARDS, focus on supporting or replacing organ functions and preventing consequential damage. This article summarizes the treatment strategies in the intensive care unit.
Types de publication
Journal Article
Review
English Abstract
Langues
ger
Sous-ensembles de citation
IM
Pagination
330-345Informations de copyright
Thieme. All rights reserved.